drugset / Trial / NCT02281591

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

NCT02281591

Phase 1 Completed 32 enrolled Bial - Portela C S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

Single centre, open-label, randomised study in four parallel groups of healthy volunteers

Timeline

Start
2006-06
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eslicarbazepine acetate Unknown 450 mg Oral
Comparator Eslicarbazepine acetate Unknown 900 mg Oral
Comparator R-licarbazepine Unknown 450 mg Oral

Indications